HIF1A and neoplasm: Consistent with previous findings in the cell‐line derived cancer model (Figure 6A,B), TZP significantly reduced the expression of the target proteins in tumor tissues, confirming that TZP inhibited the HIF‐1α‐mediated glycolytic pathway in human tumor cells (Figure 7F,G).